Endometrial cancer stage III recurrence rate

Stage III endometrial cancer is a period that is difficult to cure in clinical treatment. Basically, when the disease develops to this stage, the corresponding treatment effect is not very good, and it is easy to relapse. Therefore, it is necessary for us to understand these corresponding knowledge. Let's take a look at the recurrence rate of stage III endometrial cancer.

According to the TNM staging standard for endometrial cancer, stage III clinical endometrial cancer refers to malignant lesions with metastasis. It is a mid- to late-stage endometrial malignancy and is more common in clinical endometrial cancer types.

Whether the treatment method of stage III endometrial cancer is properly selected is an important factor affecting how long patients with stage III endometrial cancer can survive. The first choice of clinical treatment for stage III endometrial cancer is surgical treatment. For patients with stage III endometrial cancer who can tolerate surgical treatment, surgical resection can be performed first. For patients who cannot tolerate surgical treatment, blind surgical treatment is not recommended. After surgery, chemotherapy is performed according to the situation of surgical resection. The TC regimen can be selected for chemotherapy. After a course of chemotherapy, the patient's physical indicators are reviewed to see if they are normal before the subsequent chemotherapy regimen is carried out. If the patient's indicators are still abnormal or the patient's body cannot tolerate or develops drug resistance, the chemotherapy regimen should be changed in time.

Conventional surgery and chemotherapy are difficult to completely cure patients with stage III endometrial cancer. Even if the condition is temporarily relieved, it may relapse after 2-3 years. Repeated surgery and chemotherapy for these patients is not only not very helpful in controlling the patient's condition and improving survival, but may also aggravate the patient's condition and accelerate death, especially for patients with poorly differentiated endometrial cancer. Therefore, the treatment of patients with stage III endometrial cancer should not only focus on killing tumor cells in the body, but also try to improve the patient's own anti-tumor immunity as much as possible to fight cancer independently.

In view of the toxic side effects of chemotherapy and radiotherapy on the human body, autologous immune cell therapy that enhances the patient's immune function can be recommended in the treatment of stage III endometrial cancer to enhance efficacy and reduce toxicity. For stage III endometrial cancer patients with a wide range of metastases, weak physical functions, and difficulty in tolerating chemotherapy, autologous immune cell therapy can be used for combined treatment. Although the short-term effect is not as obvious as chemotherapy, the long-term effect is good, and it is effective in improving the quality of life and prolonging survival.

Autologous immune cell therapy is to use one's own cells to treat one's own cancer. By increasing the activity of one's own immune cells, regulating and enhancing the body's autonomous anti-cancer immune ability, the purpose and effect of inhibiting and killing cancer cells in the body can be achieved. The treatment of stage III endometrial cancer combined with autologous immune cell therapy can effectively improve the overall treatment effect, improve the patient's overall physical condition, effectively improve the patient's quality of life, and prolong long-term survival.